ERBB2 and breast carcinoma: When treating HER2+ breast cancer mice with ICOSL knockout, it was found that αHER2-DPP4 lost its efficacy, indicating that αHER2-DPP4 primarily exerts its therapeutic effects by targeting and degrading sICOSL (Figure S6G, H).